GlassScriptPhysician profile
Richard Duncan Minkner
NPI 1205140522
$2,517.38
in general payments reported to CMS, 2019-2025
16 companies · $482 in 2025
The $482 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.84 · 2021: $399 · 2022: $337 · 2023: $410 · 2024: $803 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,695.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $885.12 | 2022-2025 | |
| Novo Nordisk INC | $394.01 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $203.42 | 2021-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $154.06 | 2022-2025 | Arexvy, Shingrix, Bexsero |
| Dexcom, INC. | $139.42 | 2024-2025 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $136.20 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Idorsia Pharmaceuticals US INC | $130.85 | 2024 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $104.21 | 2019-2023 | Farxiga |
| Abbott Laboratories | $71.35 | 2024-2025 | Freestyle Libre 3 |
| Smith+Nephew, INC. | $68.52 | 2022 | |
| Amgen INC. | $56.86 | 2024-2025 | Tezspire, Repatha, Otezla |
| Exact Sciences Corporation | $52.70 | 2023-2024 | Cologuard Collection Kit |
| Indivior INC. | $50.05 | 2025 | Sublocade |
| Pfizer INC. | $43.02 | 2025 | |
| Xeris Pharmaceuticals, INC. | $14.19 | 2024 | Gvoke Hypopen |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $13.40 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Minkner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.